Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Moon Capital Management. This analysis is provided for institutional research purposes only and is not investment advice.
"Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as a highly mispriced compounder."
In the Q4 2025 letter, David Moon highlights that despite extensive negative geopolitical and macroeconomic headlines during 2025, stock markets rose because corporate fundamentals remained strong, with S&P 500 earnings growing by roughly 13%. He warns against the psychological trap of short-term extrapolation and notes that market sentiment is highly transitory. Moon Capital Management took advantage of this noise to initiate a high-conviction position in Molina Healthcare (MOH) at ~$160. The firm believes MOH's regulatory Medicaid rate-reset mechanisms will inevitably correct temporary, post-COVID margin pressures, offering a clear path to 2-3x upside and a fair value of up to $675 per share by 2028.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Growth Outlook
Market outlook remains above average conviction: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Risk Appetite
Risk appetite posture is above average conviction: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Forward Guidance
Forward guidance signal: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Language Signal
Tone analysis indicates high conviction language: Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
Time Horizon
Investment time horizon reflects a high conviction orientation. Moon Capital outlines how long-term corporate earnings compounding triumphed over alarming 2025 headlines, and highlights a new contrarian investment in Molina Healthcare (MOH) as ...
